STOCK TITAN

Baudax Bio, Inc. - $BXRX STOCK NEWS

Welcome to our dedicated page for Baudax Bio news (Ticker: $BXRX), a resource for investors and traders seeking the latest updates and insights on Baudax Bio stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Baudax Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Baudax Bio's position in the market.

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.63%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.58%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-55.76%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.17%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.17%
Tags
conferences clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.16%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.86%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
32.38%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.77%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.88%
Tags
Baudax Bio, Inc.

Nasdaq:BXRX

BXRX Rankings

BXRX Stock Data

950.33k
43.59M
0.02%
2.68%
3.9%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States
Malvern

About BXRX

baudax bio, inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. its lead product candidate is intravenous form of meloxicam, a non-opioid that has completed phase iii clinical trials for the management of moderate to severe pain; and is in the phase iiib clinical trials in colorectal surgery and orthopedic surgery patients to assess opioid consumption, pain intensity, and length of hospital stay with associated pharmacoeconomic parameters. the company's early-stage product candidates includes rp1000, an intermediate-acting neuromuscular blocking agent (nmba) that is in phase i clinical trial; and rp2000, an ultrashort-acting nmba, which is in pre-clinical trial; and a reversal agent, as well as dex-in, a proprietary intranasal formulation of dexmedetomidine. the company was incorporated in 2019 and is based in malvern, pennsylvania.